Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

View:
Post by M101 on May 25, 2021 11:15am

questions

I don't see the word immusafe anywhere in that release, so can we let that one die now?
RC?

And can someone square for me how today's marketing news from Promis that

"initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to private individual consumers or the general public." 

is consistent with the unrestricted retail offer from Immunity Passport? 
https://covidimmunitypassport.com/product/premium-kit-covid-19-antibodies-testing/

Is immunity Passport the JV effort?  Are we looking at a two pronged marketing strategy here or are these different products?
Gbathat?
Comment by wallpaper2 on May 25, 2021 11:28am
With 350 million shares outstanding I don't think it matters what they do.
Comment by DavidKingCanada on May 25, 2021 12:01pm
It seems like Governments and Big Business will be the primary Clients. This is actually much better than selling it to private individuals or have the product available over the counter. With any large Business its always better to deal directly with other Businesses. I have been holding PMN.to and ARFXF for a long time now and have always stated this Company will thrive. As far as the number of ...more  
Comment by M101 on May 25, 2021 1:17pm
Yes, of course it appears to be a bigger market than is being targeted by Immunity Passport, but the question is are we doing both? And then is one through the JV? Or did we just trash the JV without an announcement? And if so by mutual consent? And if so was it because of a market study? And does that study support hiring the marketing expert? Or is there no one running this ship.  I'm ...more  
Comment by Mole101 on May 25, 2021 3:00pm
b) Joint arrangement 2 (JV2) will provide the service of highly sensitive and specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. JV2 includes a jointly controlled venture (Immusafe Labs, Inc.) and jointly controlled operations. The company acquired 50% of Immusafe Labs, Inc. for $3,000. The company is ...more  
Comment by M101 on May 25, 2021 5:21pm
Thanks for the reminder that Immusafe is just a lab name, so I guess that doesn't present the copyright problem I thought. I'm still not seeing how this works with Immunity Passport, but that name didn't come from any company news release so does that problem start and end with assumptions made at this chat board? I really hope so.    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities